PMV Pharmaceuticals adds Matt Eckler and PMV Pharmaceuticals stock posts 21.60 percent YTD

Published on 10/14/2026 at 03:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Rezatapopt reached a 46.00 percent response rate in 76 patients. PMV Pharmaceuticals stock reflects a Q1 2027 filing plan.

Board change and clinical milestones

PMV Pharmaceuticals stock had gained 21.60 percent year to date by October 12, 2026.
Rezatapopt produced a 46.00 percent response rate among 76 evaluable patients.
PMV Pharmaceuticals plans a fourth-quarter 2026 data update and a first-quarter 2027 filing.

PMVP, US69353Y1038, Illustration mit AI erstellt.

PMV Pharmaceuticals (ISIN US69353Y1038) had gained 21.60 percent year to date by October 12, 2026, while the company added Matt Eckler to its board on October 5, 2026. The move comes as PMV Pharmaceuticals prepares a first-quarter 2027 regulatory filing for rezatapopt, its precision oncology candidate.

Board change precedes filing plan

As Investing.com reported on October 5, 2026, Matt Eckler joined the board. The company plans to seek accelerated approval for rezatapopt in platinum-resistant or refractory ovarian cancer involving the TP53 Y220C mutation.

Eckler brings healthcare investment and scientific research experience, according to Investing.com. PMV Pharmaceuticals describes itself as a precision oncology company developing small molecule therapies aimed at correcting cancer-related p53 mutations, according to its investor-relations profile.

Clinical data set the next test

Zacks reported on October 12, 2026, that rezatapopt produced a 46.00 percent overall response rate among 76 evaluable ovarian cancer patients. The results included four confirmed complete responses, 29 confirmed partial responses and a median response duration of 10 months among confirmed responders.

The study spans five Phase 2 cohorts, including ovarian, lung, breast and endometrial cancers. The response data are the central clinical measure for the planned regulatory path, while the filing timeline remains dependent on clinical results, execution and regulatory review.

What dates shape the pipeline?

PMV Pharmaceuticals expects to present an update covering all Phase 2 pivotal cohorts at a medical conference in the fourth quarter of 2026. The company plans its first new drug application submission in the first quarter of 2027, according to Zacks.

Three dated milestones

In August 2026, PMV Pharmaceuticals reported interim rezatapopt data showing a 46.00 percent response rate among 76 patients. On August 31, 2026, the company priced a public offering expected to generate USD 50.8 million in gross proceeds. On October 5, 2026, it added Matt Eckler to the board, according to Investing.com.

Market context for PMVP

PMVP had a market capitalization of USD 72.0 million and a 52-week range of USD 1.02 to USD 1.91 in the finance quote dated October 13, 2026. The stock trades on NASDAQ under the ticker PMVP, and the company operates in the Healthcare sector and Biotechnology industry.